IQVIA Earnings Reports

IQVIA reported a revenue of $3,958 million for the fourth quarter of 2024, representing a 2.3% increase on a reported basis and 3.0% at constant currency. GAAP Net Income was $437 million, with GAAP Diluted Earnings per Share at $2.42. Adjusted EBITDA was $996 million. The company reaffirms its 2025 outlook.

IQVIA reported Q3 2024 results with revenue of $3,896 million, a GAAP Net Income of $285 million, and an adjusted EPS of $2.84. The company has updated its full-year 2024 guidance due to delays in mega trials.

IQVIA reported second-quarter revenue of $3,814 million, a 2.3% increase year-over-year. GAAP Net Income was $363 million, with adjusted diluted earnings per share of $2.64. The R&D Solutions segment showed strong bookings of $2.7 billion, and the company updated its full-year 2024 guidance.

IQVIA reported a 2.3% increase in revenue to $3,737 million for Q1 2024. GAAP Net Income was $288 million with a GAAP EPS of $1.56. The R&D Solutions contracted backlog reached $30.1 billion, a 7.9% increase year-over-year.

IQVIA reported a 3.5% increase in revenue for Q4 2023, reaching $3,868 million. GAAP Net Income increased significantly to $469 million, and GAAP Diluted Earnings per Share rose to $2.54. The company issued full-year 2024 guidance, projecting revenue between $15,400 million and $15,650 million.

IQVIA reported a 4.9% year-over-year revenue increase in Q3 2023, reaching $3,736 million. Net income grew by 7.1% to $303 million, and adjusted EBITDA increased by 9.1% to $888 million. The R&DS segment demonstrated notable strength, with a book-to-bill ratio of 1.24x and backlog growth of 12%.

IQVIA reported a revenue of $3,728 million, a 5.3% increase year-over-year. GAAP Net Income was $297 million, up 16.0% year-over-year. Adjusted Diluted Earnings per Share was $2.43, a 0.4% decrease year-over-year.

IQVIA's first-quarter 2023 results showed revenue of $3,652 million, a GAAP net income of $289 million, and an adjusted EBITDA of $851 million. The company reaffirmed its full-year 2023 guidance.

IQVIA's Q4 2022 results showed revenue of $3,739 million, a 2.8% increase, and GAAP Net Income of $227 million. The company's Adjusted Diluted Earnings per Share was $2.78, up 9.0% year-over-year, and Adjusted EBITDA was $920 million, an 11.1% increase year-over-year. R&D Solutions quarterly bookings were over $3.1 billion, with a book-to-bill ratio of 1.51x.

IQVIA's third-quarter 2022 results showcased strong financial performance. Revenue reached $3,562 million, a 5.0% increase year-over-year. GAAP Net Income grew by 8.4% to $283 million, with adjusted diluted earnings per share increasing by 14.3% to $2.48. The company's R&D Solutions also saw quarterly bookings exceeding $2.5 billion.

IQVIA's second-quarter 2022 results showed revenue of $3,541 million, a 3.0 percent increase year-over-year, and GAAP net income of $256 million, up 46.3 percent year-over-year. Adjusted diluted earnings per share grew by 14.6 percent to $2.44, and R&D Solutions continued its strong bookings momentum with over $2.6 billion in net new business.

IQVIA reported a strong first quarter with revenue increasing by 4.7 percent year-over-year to $3,568 million. GAAP Net Income grew by 53.3 percent year-over-year to $325 million, and Adjusted EBITDA increased by 9.1 percent year-over-year to $812 million. The company also achieved record R&D Solutions services bookings and backlog.

IQVIA reported a strong Q4 2021 with revenue of $3,636 million, a 10.2% increase year-over-year. GAAP net income grew by 167.2% to $318 million, and adjusted diluted EPS increased by 20.9% to $2.55. The company also raised its full-year 2022 profit guidance.

IQVIA reported strong third-quarter results with a 21.7% increase in revenue to $3,391 million and a 158.4% increase in GAAP net income to $261 million. The company also raised its full-year 2021 guidance for revenue, Adjusted EBITDA, and Adjusted Diluted EPS.

IQVIA reported strong second-quarter 2021 results, exceeding targets across key financial metrics. Revenue increased by 36.4% year-over-year, and the company raised its full-year 2021 financial guidance due to sustained market momentum.

IQVIA reported strong first-quarter results with revenue of $3,409 million, a 23.8% increase year-over-year, and adjusted diluted earnings per share of $2.18, a 45.3% increase year-over-year. The company raised its full-year 2021 guidance for revenue, Adjusted EBITDA and Adjusted Diluted EPS.

IQVIA reported a strong fourth quarter in 2020, with revenue reaching $3,298 million, a 13.9% increase year-over-year. Adjusted diluted EPS grew by 21.3% year-over-year to $2.11, and the company raised its full-year 2021 guidance for revenue, Adjusted EBITDA and Adjusted Diluted EPS.

IQVIA reported third-quarter results with revenue of $2,786 million and Adjusted EBITDA of $604 million. The company raised full-year 2020 guidance for revenue, Adjusted EBITDA and Adjusted Diluted EPS and provided a full-year 2021 outlook for revenue $12,300 million to $12,600 million, Adjusted EBITDA $2,725 million to $2,800 million and Adjusted Diluted EPS $7.65 to $7.95.

IQVIA reported second-quarter revenue of $2,521 million and adjusted EBITDA of $483 million. The company's R&D Solutions backlog grew 13.5% year-over-year to $20.5 billion. Due to better than expected performance, the company raised its full-year 2020 guidance for revenue, adjusted EBITDA and adjusted diluted earnings per share.

IQVIA's first-quarter revenue reached $2,754 million, with adjusted diluted earnings per share at $1.50. The R&D Solutions quarterly net book-to-bill ratio was 1.42x including pass throughs, and the contracted backlog grew 14% year-over-year to $19.6 billion.

IQVIA's Q4 2019 revenue reached $2,895 million, with adjusted diluted earnings per share of $1.74, a 16.0 percent increase year-over-year. The company highlighted significant wins in Technology & Analytics Solutions and continued strong momentum in R&DS.